These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms do not affect methadone maintenance treatment in HCV-positive patients. Author: Sutlović D, Ključević Ž, Kuret S. Journal: Arh Hig Rada Toksikol; 2020 Dec 31; 71(4):353-358. PubMed ID: 33410778. Abstract: The aim of this study was to determine the influence of ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms on methadone metabolism in patients with hepatitis C virus (HCV) undergoing methadone maintenance treatment (MMT). The study included 35 participants undergoing MMT, who were divided in three groups: HCV-positive (N=12), HCV-negative (N=16), and HCV clinical remission (CR) (N=7). The concentrations of methadone and its main metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) were determined with gas chromatography-mass spectrometry. The patients were genotyped for ABCB1 rs1045642, CYP2B6 rs3745274, CYP3A4 rs2242480, and CYP3A4 rs2740574 polymorphisms. Differences between single nucleotide polymorphism (SNP) genotypes and methadone-to-EDDP ratio were analysed with one-way ANOVA, which showed no significant difference between the genes (p=0.3772 for ABCB1 rs1045642, p=0.6909 for CYP2B6 rs3745274, and p=0.6533 for CYP3A4 rs2242480). None of the four analysed SNP genotypes correlated with methadone-to-EDDP concentration ratio. A major influence on it in hepatitis C-positive patients turned out to be the stage of liver damage. Cilj ovoga istraživanja bio je utvrditi utjecaj polimorfizama gena ABCB1, CYP2B6 i CYP3A4 na metabolizam metadona u bolesnika/ovisnika s pozitivnim nalazom virusa hepatitisa C (HCV) na metadonskoj terapiji održavanja. Istraživanje je provedeno na uzorku od 35 sudionika na metadonskoj terapiji održavanja, podijeljenih u sljedeće skupine: HCV pozitivni (N=12), HCV negativni (N=16) i oni s kliničkom remisijom HCV-a (CR) (N=7). Koncentracije metadona i njegova glavnog metabolita 2-etiliden-1,5-dimetil-3,3-difenilpirolidina (EDDP) utvrđene su plinskom kromatografijom – masenom spektrometrijom. U sudionika su analizirani genski polimorfizmi ABCB1 rs1045642, CYP2B6 rs3745274, CYP3A4 rs2242480 i CYP3A4 rs2740574. Jednosmjerna analiza varijance (engl. one-way ANOVA) nije pokazala statistički značajne razlike između genotipova jednonukleotidnih polimorfizama (engl. single-nucleotide polymorphism, krat. SNP) u omjeru koncentracije metadona i EDDP-a (p=0,3772 za ABCB1 rs1045642; p=0,6909 za CYP2B6 rs3745274 F=0,374 i p=0,6533 za CYP3A4 rs2242480). Nijedan od četiriju analiziranih SNP genotipova nije korelirao s omjerom koncentracije metadona i EDDP-a. U bolesnika/ovisnika koji su bili pozitivni na HCV na taj je omjer ponajviše utjecao stupanj oštećenja jetre.[Abstract] [Full Text] [Related] [New Search]